CD NPs demonstrate a greater potential to induce apoptosis, inhibit hypoxia-inducible factor genes, and eradicate CD44+ cancer stem cells by downregulating key genes associated with stemness, chemoresistance, and metastasis, while also reducing hepatic tumor markers, such as α-fetoprotein. The gene discussed is CD44; the disease is cancer.